Tivantinib and Regorafenib for the Treatment of Liver Cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
Clinical Pearls
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
- Tivantinib is in phase III development for liver cancer
- A phase II study comparing tivantinib to placebo showed no dramatic benefit in all-comers
- An analysis showed high MET expression was associated with worse prognosis, and high MET patients saw benefit from tivantinib versus low MET
- Regorafenib has shown activity in colorectal cancer and GIST
- A phase II study of regorafenib demonstrated provocative survival data for patients who have progressed on sorafenib
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
